PTEN and glioma: In fact, PTEN mutations have been correlated with a lack of sensitivity to anti-PD-1/PD-L1 therapy and, therefore, combinatorial strategies between PD-1/PD-L1 inhibitors and PI3K/AKT targeting drugs are being proposed to overcome resistance to immune checkpoint inhibition in human gliomas [53,55].